Santalis Pharmaceuticals
US-based Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of Quintis Ltd. of Perth, Australia (ASX:QIN). Santalis was formed to develop a range of OTC and prescription products based on the botanical drug substance produced by Quintis' Santalum album trees. Santalis has the world-wide exclusive rights to Quintis' Sandalwood Album Oil (SAO) for healthcare uses. Quintis is the world's largest producer of this essential oil and is the only supplier of pharmaceutical grade SAO from sustainably-grown trees. Santalis is developing SAO under the FDA's botanical drug development guidelines, with a current focus on dermatology. Indications of particular interest include acne, rosacea, atopic dermatitis/eczema, psoriasis and viral skin diseases such as Molluscum contagiosum and warts caused by human papilloma virus (HPV).
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
3
tools in use
Monthly traffic
766
organic / mo
Sign up free to see all 4 verified contacts at Santalis Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Santalis Pharmaceuticals
4 distinct titles indexed · top 4 shown.
- 1businesd
- 1clinical project manager
- 1lecture
- 1santali
Sign up to unlock all 4 contacts at Santalis Pharmaceuticals
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Santalis Pharmaceuticals
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.